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Hepatic iron overload is common in patients undergoing hematopoietic cell transplantation. We showed
previously in a murine model that transplantation of allogeneic T cells induced iron deposition and down-
regulation of hepcidin (Hamp) in hepatocytes. We hypothesized that hepatic injury was related to dis-
rupted iron homeostasis triggered by the interaction of Fas-ligand, expressed on activated T cells, with Fas on
hepatocytes. In the current study, we determined the effects of modiﬁed expression of the Flice inhibitory
protein (FLIP long [FLIPL]), which interferes with Fas signaling, on the impact of Fas-initiated signals on the
expression of IL-6 and Stat3 and their downstream target, Hamp. To exclude a possible contribution by other
pathways, we used agonistic anti-Fas antibodies (rather than allogeneic T cells) to trigger Fas signaling.
Inhibition of FLIPL by RNA interference resulted, as expected, not only in enhanced hepatocyte apoptosis in
response to Fas signals, but also in decreased levels of IL-6, Stat3, and Hamp. In contrast, overexpression of
FLIPL protected hepatocytes against agonistic anti-Fas antibody-mediated apoptosis and increased the levels
of IL-6 and Stat3, thereby maintaining the expression of Hamp in an NF-kBedependent fashion. In vivo
overexpression of FLIPL in the liver via hydrodynamic transfection, similarly, interfered with Fas-initiated
apoptosis and prevented down-regulation of IL-6, Stat3, and Hamp. These data indicate that Fas-dependent
signals alter the regulation of iron homeostasis and suggest that signals initiated by Fas may contribute to
peritransplantation iron accumulation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
There is evidence that iron overload, which is common in
patients undergoing hematopoietic cell transplantation
(HCT), has a negative impact on survival after allogeneic HCT
[1,2], which extends beyond the acute post-HCT period [3].
Gordon et al. reported an increase in nontransferrin-bound
iron after transplantation conditioning [4]. We showed in
a NOD.CB17-Prkdcscid/NcrCrl (NOD/SCID) mouse model (not
requiring pretransplantation conditioning) that trans-
plantation of allogeneic T cells resulted in hepatic iron
deposition and down-regulation of the iron-regulator hep-
cidin (Hamp) in hepatocytes [5]. Activated (donor-derived)
T lymphocytes express CD178, the cognate ligand for Fas
(CD95) [6,7], and interact with Fas-expressing recipient
tissues, including the liver. The liver is involved in the
regulation of iron homeostasis [8] and is a major target ofedgments on page 1218.
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13.05.012graft-versus-host disease (GVHD) [9], although a clear rela-
tionship between iron overload and GVHD has not been
established. Fas-triggered signals typically initiate apoptosis,
which is a histologic hallmark of GVHD.
Hepcidin is a peptide hormone that is essential for the
regulation of iron homeostasis via its interaction with fer-
roportin1 [10]. Several signals affect the activation of Hamp,
including IL-6 and STAT3 (signal transducer and activator of
transcription 3) [11]. Based on earlier data [5], we hypothe-
sized that the balance of Hamp activating and inhibiting
factors was altered via Fas signals. To circumvent signals
induced by a transplantation conditioning regimen, we used
a model of parent (P) into F1 hybrid transplantation to
investigate the effects of (semi-) allogeneic cells on iron
homeostasis andHamp expression inwild-type recipients. To
further characterize the relevance of the role of Fas-mediated
signals, we then used agonistic anti-Fas antibodies, which
allowed us to exclude other signals that may be mediated by
allogeneic cells, such as IL-1b, IL-2, or TNF-a, and permitted
a side-by-side comparison of the responses of murine and
human hepatocytes in vitro. We determined Fas-induced
expression of IL-6, Stat3, and Hamp, dependent on inhibi-
tion or overexpression of FLIP (ﬂice inhibitory protein),
which interferes with Fas signaling [12]. Our results show
profound effects of Fas signaling, not only on hepatocyte
apoptosis but also on hepcidin expression.Transplantation.
Figure 1. T lymphocyte transplantation, serum iron, and hepcidin expression in hepatocytes. F1 mice received semiallogeneic P or syndenic F1 T lymphocytes. Serum
iron was determined on days 0, 7, and 14, and hepcidin mRNA in hepatocytes was determined at autopsy (day 14) (P < .05).
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Reagents
Hamster anti-mouse Fas monoclonal antibody (MAB) (referred to as
aFas, clone JO2) was obtained from BD Biosciences (San Diego, CA), mouse
anti-human Fas MAB (clone CH11) from Upstate (Lake Placid, NY), rabbit
anti-human-hepcidin-25 antibody (#ab 30760) from Abcam (San Francisco,
CA), and rabbit anti-human GFP antibody (#2555) from Cell Signaling
(Boston, MA). Duplex small interference RNA (siRNA) oligonucleotides
(oligos) for the long splice variant of FLIP (FLIPL) were from Qiagen
(Valencia, CA). A GFP-containing plasmid, FLIPL-IRES-GFP, and a scrambled
sequence IRES-GFP control were generated in our laboratory. The plasmids
contain a hepatic locus control region from the apolipoprotein gene, a liver-
speciﬁc a1-antitrypsin promoter, a portion of human factor IX cDNA, and
a bovine growth hormone polyadenylation signal [13]. Lipofectamine
RNAiMAX and Lipofectamine LTX were from Invitrogen (Carlsbad, CA).
Caspase-8 inhibitor Z-IETD-FMK was obtained from BD Pharmingen (San
Diego, CA).
Cell Lines
Nontransformedmurine and human hepatocyte cell lines, NMH (Balb/c-
derived) and HH4, were developed by Jean Campbell, PhD [14,15].
Mice
C57Bl/6 [H-2b], Balb/c [H-2d], C3H [H-2k], and A/J [H-2a] mice were
purchased from Jackson Laboratories (Bar Harbor, ME). Female C57BL/6 
C3H [H-2b/k] and Balb/c  A/J [H-2d/a] F1 hybrids were bred at the animal
facility of the Fred Hutchinson Cancer Research Center (FHCRC). Mice were 6
to 8 wk old at the time of the experiment. Experiments were approved by
the Institutional Animal Care and Use Committee of the FHCRC.
Transplantation and Analysis of Outcome
Three  107 CD3þ T cells from C57BL/6 parental semiallogeneic
(referred to as allogeneic) donors were injected via the tail vein into F1
C57BL/6  C3H recipients (low constitutive iron levels); similarly, 3  107
T cells from Balb/c donors were injected into F1 Balb/c  A/J recipients (high
constitutive iron levels). Syngeneic F1 into F1 controls were carried out in
parallel. Blood samples for the determination of iron levels were obtained on
days 7 and 14, and mice were killed on day 14. Hamp expression and iron
content in the liver were determined as describe previously [5]. Serum iron
levels weremeasured using Quanti-Chrom Iron Assay Kit (BioAssay Systems,
Hayward, CA).
In Vitro Transfection
Murine and human cell lines (NMH and HH4) or primary murine
hepatocytes were plated in 12- (6-) well plates at 1 105 (5  105) cells per
well in 1 mL medium without antibiotics, grown to 90% to 95% conﬂuence,and transfected with siRNA oligos (FLIPL inhibition) or FLIPL-containing
vectors for FLIPL-GFP (or control GFP) overexpression, using Lipofectamine
RNAiMAX or Lipofectamine LTX.
Hydrodynamic In Vivo Transfection
Based on dose-ﬁnding experiments, 150 mg plasmid (FLIPL-GFP or
scrambled-GFP), diluted in 2 mL phosphate-buffered saline, were injected
over 6 to 8 seconds into the tail veins of Balb/c mice [13].
Harvest of Primary Hepatocytes
Mice were anesthetized with avertin, a 27G needle was inserted into the
portal vein, and 50 mL calcium-free Hank’s balanced salt solution (Sigma, St.
Louis, MO) supplementedwith .02% ethylene glycol-bis (b-aminoethylether)
N,N,N0 ,N0-tetraacetic acid (Sigma) was infused at 37C at 5 mL/min, followed
by 50 mL of Hank’s balanced salt solution supplemented with .04% colla-
genase (Invitrogen). An incision in the inferior vena cava allowed for outﬂow
of excess solution. The liver was chopped, and hepatocyte suspensions were
ﬁltered through a 70-mm cell strainer, washed PBS, and cultured in adhesion
medium [13].
Liver Harvest for Immunohistochemistry and Immunoﬂuorescent
Staining
In separate experiments, livers from hydrodynamically transfected mice
were harvested without preceding collagenase perfusion. Liver tissues were
formalin-ﬁxed for 72 hours, and 4-mm sections were cut, deparafﬁnized, and
rehydrated in Tris-buffered saline (TBS) containing .1% Tween-20 (TBS-T).
Antigen retrieval was performed using used a steamer (Black and Decker,
Towson, MD) with a 20-minutes exposure in preheated Trilogy buffer (Cell
Marque, Rocklin, CA) followed by 20-minutes cooling. Slides were rinsed
3 times in wash buffer, and subsequent staining was performed at room
temperature using an autostainer (DAKO, Carpinteria, CA). Slides were then
blocked for 10 minutes in 15% horse serum (Vector Labs, Burlingame, CA) in
TBS containing 1% BSA. Sections were stained with anti-GFP antibody (Cell
Signaling) and anti-hepcidin antibody (Abcam) that were diluted 1:50
(.42 mg/mL), incubated on the tissue for 60 minutes, and washed with wash
buffer.
Antibody staining was detected using biotinylated horse anti-mouse
anti-serum (BA-2000, Vector Labs) at 1:200 for 30 minutes, followed by
horseradish peroxidaseelabeled strep-avidin (016-030-084, Jackson Immu-
noResearch, West Grove, PA) at a dilution of 1:2000 for 30 minutes. Staining
was visualized with 3,30-diaminobenzidine (DAKO) for 8 minutes, and slides
were counterstainedwith a 1:4 dilution of hematoxylin (DAKO) for 2minutes.
An irrelevant, control concentration-matched, isotype-stained slide was
evaluated for background staining for each tissue sample. The expression of
GFP and hepcidin were determined [5] using a Nikon E800 microscope
(Experimental Histopathology Shared Resource, FHCRC, Tokyo, Japan).
Figure 2. FLIPL expression and apoptosis in murine (NMH) and human (HH4) hepatocyte cell lines and in primary murine hepatocytes. (A, B, and C) Unmodiﬁed cells;
(D, E, and F) cells with FLIPL inhibition (siFLIPL); (G, H, and I) cells overexpressing FLIPL (over-FLIPL). Unmodiﬁed cells (A, B, and C) were treatedwith 2 concentrations of
agonistic aFas antibody (JO2, 375ng/mL and750ng/mL formurine cells; andCH11, 250ng/mL and500ng/mL forhumancells). FLIPLmodiﬁed cells (D-I)were treatedwith
JO2, 750ng/mL (murine cells) andCH11, 500ng/mL (human cells), respectively; the dosewas based onﬁndings inunmodiﬁed cells. The extentof apoptosis as determined
at 24 hours by Annexin V staining is indicated on the vertical axis. Shown are the mean  SEM of 3 to 5 experiments. Note different scales of the vertical axis.
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Mice were killed by CO2 inhalation at 2, 4, or 6 hours after treatment
with aFas, livers were minced through a 70-mm mesh, and total RNA was
extracted as described [14].
FACS Analysis
Apoptosis was determined by ﬂow cytometry, using FITC-conjugated
Annexin V as described [16]. Brieﬂy, hepatocytes, modiﬁed or unmodiﬁed,
were cultured in the presence or absence of aFas JO2 (375 ng/mL and
750 ng/mL) or aFas CH4 (500 ng/mL and 1000 ng/mL), and apoptosis was
determined after 24 hours.
Analysis of Human and Murine Cytokines by Real-Time PCR
Quantitative reverse transcriptase PCR (qRT-PCR) was carried out using
the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems,
Foster City, CA). cDNA was generated with the mMACS One-Step cDNA kit
(Miltenyi Biotec, Auburn, California) using a starting population of 5  104
hepatocytes. qRT-PCR was performed with SYBR Green Master Mix and
3-step standard cycling conditions using sequence-speciﬁc primers. The
melting curves were examined to ascertain that a single product was
ampliﬁed. For quantitative analysis, the observed copy numbers of each
gene were normalized to the expression of b-actin. Additionally, we veriﬁed
that the PCR efﬁciencies of the ABI assays were >95% and that the slopes of
the linear portion of the ampliﬁcation curves varied by <5%.
Human probes
FLIPL (Hs00153439_m1), HAMP (Hs00221783_m1), STAT3
(Hs00374280_m1), IL-6 (Hs00985639_m1), and human b-actin
(Hs99999903_m1) were purchase from Applied Biosystem.Murine probes
FlipL (Mm01255578_m1), Hamp (Mm04231240_s1), Stat3
(Mm01219775_m1), IL-6 (Mm00446191_m1), and mouse b-actin
(Mm00607939_s1) were purchase from Applied Biosystem.
Electrophoretic Mobility Shift Assay
One  107 cells were harvested and washed. Nuclear proteins were
extracted using Nuclear Extraction Kit (Panomics, Fremont, CA) and incu-
bated with a biotin end-labeled NF-kB oligonucleotide (50-CCACAGT
TGGGATTTCCCAA CCTGACCAG-30) for 30 minutes at room temperature.
A cold probe was included as a negative control. DNA protein complexes
were separated from free oligonucleotides on 6% native polyacrylamide
gels. Horseradish peroxidase was used to enhance chemoluminescence
(Pierce Biotechnology, Inc., Rockford, IL), and membranes were exposed to
ﬁlm.
Western Blot Analysis
Liver cell lysates were prepared by sonicating hepatocytes for 4 minutes.
Fractions were cleared by centrifugation at 20000  g for 10 minutes.
Protein concentrations were quantiﬁed by bicinchoninic acid assay (Pierce
Biotechnology), and equal amounts of protein (30 mg) from each lysate were
diluted in Laemmli SDS sample buffer and resolved by electropheresis on 4%
to 12% Bis-Tris pre-cast NuPage gels (Invitrogen) in running buffer (50 mM
2-(N-morpholino) ethane sulfonic acid 50 mM Tris base, .1% SDS, and 1 mM
EDTA) as per the manufacturer’s instructions. The proteins were then
transferred to polyvinylidene diﬂuoride membranes for immunoblotting.
The membranes were blocked in 5% nonfat dry milk diluted in TBS-T for
1 hours at room temperature and then incubated overnight at 4C in 5%
nonfat dry milk/TBS-T containing either rabbit anti-STAT3 antibody (1:1000,
Figure 3. Gene expression in hepatocyte cell lines and primary hepatocytes transfected with FLIPL speciﬁc (siFLIPL) to inhibit FLIPL or scrambled (SCR) siRNA and
treated with aFas. (A and C) mRNA expression of FlipL, Hamp, IL-6, and Stat3 in murine NMH cells and primary hepatocytes determined by RT-PCR. (B) Expression of
FLIPL, HAMP, IL-6, and STAT3 in human HH4 cells. Changes in gene expression are shown as fold increase over expression in unmodiﬁed controls (mean  SEM of 3
experiments). The expression pattern was altered signiﬁcantly in cells transfected with FLIPL speciﬁc siRNA compared with SCR controls, in both vehicle-treated
controls (Veh) and in aFas- (JO2; CH11) treated cells. (D) Western blots of cell lysates of murine NMH and human HH4 cells transfected with FLIPL speciﬁc
(siFLIPL) or scrambled siRNA (SCR) and treated with aFas at 2 doses. Protein levels of FLIPL, STAT3, phospho STAT3, and NF-kB were reduced in siFLIPL cells in a dose-
dependent fashion. The doses of aFas (JO2) were 375 and 750 ng/mL in NMH cells; for human HH4 cells the doses of aFas (CH11) were 250 and 500 ng/mL. b-Actin
served as loading control.
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or anti-p65 antibody (1:1000, Cell Signaling). Secondary goat anti-rabbit
antibodies (1:1000; Cell Signaling) conjugated to horseradish peroxidase
were used for enhanced chemoluminescence (Pierce Biotechnology), and
membranes were exposed to ﬁlm.
Statistical Analysis
Apoptosis, quantitated as the mean  SEM of the FITC-Annexin V ﬂuo-
rescent intensity, was determined by ﬂow cytometry. Two independent
sample values were compared using the 2-sample t-test; P < .05 was
considered signiﬁcant.
RESULTS
Iron Levels and Hamp Expression After Allogeneic T Cell
Infusion
As shown in Figure 1, syngeneic recipients showed stable
plasma iron levels over 7 to 14 days after transplantation.
Recipients of allogeneic T cells, in contrast, showed a biphasic
response in plasma iron, more pronounced in the strainwith
low constitutive than in mice with high constitutive plasma
iron levels. Expression of Hamp in allogeneic recipients was
signiﬁcantly lower than in syngeneic recipients (P < .05).
Hepatic iron content in C57BL/6  C3H mice that underwent
tranplantation with allogeneic cells was higher than in
syngeneic recipients (290  112 mg/g dry weight versus
194 65 mg/g dryweight; n¼ 3, P¼ .045). Hepatic iron levels
were not determined in Balb/c  A/J mice. Thus, although
less pronounced than in NOD/SCID mice, changes in iron
content in allogeneic recipients were distinctly different
from those in syngeneic recipients.FLIPL Expression Alters Fas-Initiated Apoptosis in
Hepatocytes
We had shown previously that hepatic responses similar
to those observed with allogeneic cells were also observed
with the use of agonistic anti-Fas antibody [17]. Speciﬁcally,
we had shown that aFas (JO2, at 250 to 1000 ng/mL for
murine cells; CH11, at 250 to 500 ng/mL for human cells)
effectively induced apoptosis in murine (NMH) and human
(HH4) hepatocyte lines, respectively [14]. Current results
conﬁrm those data (Figure 2A-C) and show that inhibition of
FLIPL enhanced apoptosis not only in cell lines but also in
primary murine hepatocytes (Figure 2D-F). Conversely,
overexpression of FLIPL decreased the extent of apoptosis
(Figure 2G-I).In Vitro Hepcidin (Hamp) Expression in Response to
Inhibition or Overexpression of FLIPL
After siRNA-mediated inhibition of FLIPL in hepatocytes,
IL-6, Stat3, and Hamp mRNA were down-regulated
(Figure 3A-C); this was reﬂected in corresponding changes
in protein levels (Figure 3D). In addition, p65, a component of
NF-kB, was down-regulated (Figure 3D), suggesting that
FLIPL-dependent signals also affected NF-kB.
Responses in hepatocytes overexpressing FLIPL showed
the opposite. IL-6, Stat3, and HampmRNAwere up-regulated
(Figure 4A-C), and expression of STAT3 and phospho-STAT3
protein was increased (Figure 4D). Also, levels of p65 were
up-regulated after Fas signaling (Figure 4D).
Figure 4. Gene expression in hepatocyte cell lines and primary hepatocytes overexpressing FLIPL (over-FLIPL) or a scrambled sequence (SCR) and treated with aFas.
(A and C) Murine NMH cells and primary hepatocytes; (B) human HH4 cells. Overexpression of FLIPL basically resulted in a pattern opposite to that seen with
inhibition of FLIPL (see Figure 1). Treatment with aFas (JO2, murine or CH11, human, respectively) resulted in up-regulation of Hamp, IL-6, and Stat 3. The pattern was
similar but less prominent in vehicle-treated controls. Shown are the mean  SEM of 3 or 4 experiments. (D) Western blots of cell lysates of murine NMH and human
HH4 cells overexpressing FLIPL (over-FLIPL) or a scrambled sequence (SCR). Shown are protein levels of FLIPL, STAT3, phospho STAT3, and p65. aFas antibody was used
at the doses indicated (ng/mL). b-Actin served as loading control. (Note different vertical scale in A, B, and C.)
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Kinetics ofHamp expression after treatment with aFas JO2
in unmodiﬁed mice is illustrated in Figure 5A. aFas exposure
induced a rapid increase in Hamp levels followed by a decline
to below baseline by 4 to 6 hours.
The transfection efﬁciency of FLIPL-GFP (or control
plasmid) in liver was 30% at 16 hours after injection of 150 mg
plasmid (Figure 5B). At 16 hours, transfected mice were
treated with aFas (JO2, .4 mg/g), and after 4 hours intact livers
or hepatocytes (after collagenase perfusion) were harvested.
Overexpression of FLIPL up-regulated IL-6, Stat3, and Hamp
as determined by real-time PCR and immunoﬂuorescent
staining (Figure 5C,D). All control mice injected with aFas
died within 4 hours, whereas mice overexpressing FLIPL in
the liver survived 2 to 3 times longer (Figure 5E) (P ¼ .001).Both Fas and FLIPL Activate NF-kB in Hepatocytes and
Alter Hepcidin Expression
NF-kB mediates IL-6 expression [18], and FLIPL is impli-
cated in the regulation of NF-kB [19,20]. We therefore
determined the effect of aFas and FLIPL expression on NF-kB
activity. aFas (JO2) induced activation of NF-kB as deter-
mined by electrophoretic mobility shift assay (Figure 6, lanes
4 versus lanes 3). Inhibition of FLIPL (Figure 6A) decreased
NF-kB activity (lane 5 versus 3), an effect partially overcome
by aFa (lane 6 versus 5). Overexpression of FLIPL (Figure 6B)
increased NF-kB activity modestly (lane 5 versus 3); aFas
enhanced that effect (lane 6 versus 5). These ﬁndings are
supported by the analysis of nuclear extracts (Figure 6C):
p65/phosp65 levels were reduced with FLIPL inhibition andincreased with overexpression of FLIPL. Upon exposure to
aFas, FLIPL expression increased and then rapidly declined
(Figure 6D). P65 expression increased by 2 to 4 hours and
then gradually decreased. If NF-kB activation was blocked by
an IkB Kinase-IV inhibitor, only low p65 levels were detect-
able and only faint bands of FLIPL were visualized, indicating
that FLIPL expression was modiﬁed by NF-kB activity
(Figure 6D). IL-6, a potent inducer of Hamp, is also regulated
by NF-kB, and blockade of NF-kB with IkB Kinase inhibitor
resulted in down-regulation of IL-6, Stat3, and Hamp mRNA.
Comparable results were achieved via inhibition of FLIPL by
siFLIPL (Figure 6E), suggesting a regulatory loop involving
FLIPL and NF-kB (Figure 7).
Overexpression of FLIPL Reduces Caspase-8 Levels in
Hepatocytes
FLIPL opposes caspase-8, thereby potently interfering
with signaling through Fas and other death receptors
[21-24]. Of note, overexpression of FLIPL was associated with
reduced levels of total caspase-8 (inhibition of FLIPL had no
signiﬁcant effect) (Figure 7A,B), and direct inhibition of
caspase-8 was followed by increased IL-6, Stat3, and Hamp
mRNA (Figure 7C). These data suggest that, in addition to
FLIPL-dependent signals, directly caspase-8erelated effects
may modify iron homeostasis (Figure 7).
DISCUSSION
We observed previously that NOD/SCID mice that
underwent tranplantation with allogeneic T lymphocytes
accumulated iron in hepatocytes while, contrary to expec-
tations, down-regulating hepcidin and increasing the
Figure 5. Overexpression of FLIPL in mouse liver by hydrodynamic transfection and effect on gene expression and survival after treatment with agonistic aFas
antibody JO2. (A) JO2 was given at .4 mg/g body weight; 4 mice per time point. Changes in Hamp expression are expressed as fold increase in comparison with PBS-
treated controls. There was a steep increase in Hamp levels followed by a decline to below baseline levels by 4 to 6 hours. (B) Dose response and time course of
transfection with the FLIPL-GFP construct. The highest efﬁciency was obtained at 16 hours with injection of 150 mg of plasmid DNA. Brown staining reﬂects the
presence of GFP (magniﬁcation 20). (C) Hepcidin expression in mouse liver after hydrodynamic transfection and treatment with aFas JO2. Upper row shows results
in livers from mice transfected with the FLIPL-GFP containing plasmid, the lower row with the control-GFP plasmid. The left panels show staining for hepcidin (long
white arrows), middle panels for GFP (short yellow arrows), and right panels the merged pictures. Strong autoﬂuorescence is present (left panels). The merged picture
(right panel, upper row) shows co-localization of FLIPL-GFP (light green) and hepcidin (orange) signals in the same hepatocyte. Only weak hepcidin signals are
identiﬁable in panels in the bottom row, not showing distinct co-localization of hepcidin with control-GFP expressing hepatocytes (original magniﬁcation 40). (D)
mRNA expression of Hamp, IL-6, and Stat3 in murine hepatocytes transfected with murine FLIPL versus a scrambled sequence (SCR) as determined by RT-PCR. At 16
hours after transfection, mice were treated with aFas JO2 at .4 mg/g body weight and killed after 4 hours. The liver was harvested, and whole liver lysates were
prepared for analysis. Expression of Hamp, IL-6, and Stat3 was increased in FLIPL transfected cells but decreased in controls (SCR). (E) Survival of unmodiﬁed mice
(control) or mice with hepatic overexpression of FLIPL (over-FLIP) after treatment with aFas JO2 at .4 mg/g body weight.
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wild-type and transferrin receptor 2 mutant mice, we also
showed profound dysregulation of plasma iron levels [17]
and induction of apoptosis in hepatocytes [14] in response
to agonistic anti-Fas antibody JO2. Because alloactivated
T cells express Fas ligand, we hypothesized that the
T celleinduced alterations in mouse livers were mediated viaFas [25]. The interpretation of results in allogeneic trans-
plantations in wild-type mice is complicated by the fact that
generally recipients need to be conditioned, and condi-
tioning by itself has potent effects on gene expression.
Therefore, in the present study, we conﬁrmed our basic
hypothesis of disruption of iron regulation by allogeneic cells
in a P into F1 (wild-type) model, where no recipient
Figure 6. NF-kB activation in hepatocytes by aFas (JO2) treatment or overexpression of FLIPL. Electrophoretic mobility shift assays for NF-kB in NMH hepatocytes (A)
with inhibition of FLIPL [siFLIPL] and (B) with overexpression of FLIPL [Over-FLIPL]) Fas signaling triggered by aFas JO2 resulted in activation of NF-kB (lane 4 versus
lane 3). Inhibition of FLIPL (A) decreased NF-kB activity (lane 5 versus 3); this effect was partially overcome by exposure to aFas (lane 6 versus lane 5). Overexpression
of FLIPL (B) marginally increased NF-kB activity (lane 5 versus lane 3); exposure to aFas enhanced that effect (lane 6 versus lane 5). (C) Findings from A and B are
supported by the analysis of nuclear extracts: p65/phosp65 levels were reduced with FLIPL inhibition and increased with overexpression of FLIPL. Histone H2 served
as loading control. (D) Left panel shows protein levels of intrinsic FLIPL and p65 in hepatocytes. JO2 was used at 1000 ng/mL, and cells were harvested at 0 to 16 hours.
The right panel shows the effect of IKK inhibitor (300 nM). Cells were harvested at 0 to 14 hours. b-Actin served as loading control. (E) Changes in expression of Hamp,
IL-6, and Stat3 in NMH cells exposed to JO2 (Fas), JO2 plus IKK inhibitor, or JO2 þ IKK inhibitor in the presence of FLIPL inhibition (siFLIPL). Changes in gene expression
are shown as fold change compared with untreated controls (mean  SEM of 3 experiments). The expression patternwas altered signiﬁcantly in cells treated with IKK
inhibitor and in cells with FLIPL inhibition (siFLIPL).
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hypothesis that the observed effects are Fas dependent by
using a Fas-speciﬁc agonistic MAB. This approach allowed usto exclude other potentially relevant signals derived from
allogeneic cells such as IL-1b, TNF-a and IL-2, or toll-like
receptor dependent pathways, among others.
Figure 7. Caspase-8, FLIPL, and iron homeostasis: a working model. (A and B) Total caspase-8 expression by Western blotting in murine (NMH) and human (HH4)
hepatocyte cell lines with inhibition (siFLIPL) or overexpression of FLIPL (Over-FLIP), with or without exposure to aFas (JO2 and C11, respectively); SCR ¼ scrambled
control. b-Actin served as loading control. (C) Expression of Hamp, IL-6, and Stat3 in murine (NMH) and human (HH4) hepatocyte cell lines treated with JO2 or C11,
respectively, in the absence or presence of caspase-8 inhibitor at 2 concentrations. Changes in gene expression are shown as fold increase over unmodiﬁed controls
(mean  SEM of 3 experiments). The expression pattern was altered signiﬁcantly in the presence of a caspase-8 inhibitor (both at 5 mM and 10 mM) (JO2; CH11). (D)
Proposed working model. DISC ¼ death-inducing signaling complex.
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and liver iron content in F1 hybrids that underwent tran-
plantation with parental cells, accompanied by down-
regulation of Hamp, in comparison with F1 recipients of
syngeneic cells, in agreement with the observation in
immunodeﬁcient mice [5], although the extent of hepatic
iron deposition was less. Additional preliminary data with Tcells form gld donors (lacking Fas ligand) showed an increase
in Hamp and a decrease in ferroportin1 expression at 7 to
14 days (H.J. Deeg, 2012), in strong support of our Fas-based
hypothesis. The role of Fas was therefore further character-
ized in the present studies. As expected, treatment with aFas
induced apoptosis and down-regulated Hamp expression in
murine and human hepatocyte cell lines as well as in primary
X. Li et al. / Biol Blood Marrow Transplant 19 (2013) 1210e12191218murine hepatocytes. Because increasing evidence demon-
strates that IL-6 has a protective role during liver injury and
is amajor growth factor protecting against cell death [26-30],
we focused on the role of the IL-6/STAT3 pathway in Fas-
initiated effects on iron homeostasis. Because Fas-mediated
signals are blocked or modulated by FLIPL, we wanted to
determine whether alterations of FLIPL expression would
also affect regulation of hepcidin. The combined results ob-
tained with inhibition and overexpression of FLIPL strongly
indicate that Fas-dependent signals impact iron homeostasis.
Inhibition of FLIPL resulted in down-regulation of IL-6, Stat3,
and Hamp mRNA. The converse results were observed after
overexpression of FLIPL, with IL-6, Stat3, and Hamp being up-
regulated. This was true not only in cell lines in vitro but also
in mouse liver in vivo after hydrodynamic transfection.
Although manipulation of FLIPL by itself affected the
expression of iron regulatory genes, this effect was ampliﬁed
after exposure to aFas.
FLIP is thought to be the molecular switch that allows Fas
to promote cell proliferation versus mediating apoptosis
[31-33]. FLIPL, 1 of the 3 isoforms of FLIP, exerts strong
antiapoptotic function [19]. However, FLIPL also mediates
activation of NF-kB by recruiting adaptor proteins, such as
Fas-associated death domain [23,34,35], and NF-kB potently
promotes expression of IL-6 [18], which in turn is followed by
STAT3 phosphorylation [36] and induction of hepcidin [37].
Conﬂicting data have been reported on NF-kB responses
to aFas (JO2) signaling in hepatocytes [38,39]. Our experi-
ments support the concept that Fas-mediated signals
enhance DNA binding of NF-kB, regardless of the sensitivity
or resistance to Fas-mediated cell death [40]. However, the
regulation may be more complex. Although others reported
that FLIPL inhibits Fas-mediated NF-kB activation [35], the
present data show that overexpression of FLIPL, in fact,
enhanced NF-kB activity. Conceivably, the difference was
dependent on the cell types used and the method of over-
expressing FLIPL.
Further, FLIPL interacts with caspase-8 and Fas-associated
death domain, forming an apoptosis-inhibiting complex [41].
Interaction of caspase-8 with the N-terminus of FLIPL
can induce robust NF-kB activation and IL-6 expression
[18,42-45], supporting the notion that caspase-8 inhibition
will affect Hamp expression, in agreement with the present
data.
Thus, we propose the model shown in Figure 6D. aFas
signals activate NF-kB, and this effect is modulated by FLIPL,
whichmay favor either cell death (apoptosis) or survival. The
survival pathway involves IL-6 and STAT3 and in turn is
associated with up-regulation of hepcidin. How additional
signals directly related to caspase-8 contribute to this
outcome remains to be determined. Taken together, the data
support a role of Fas-mediated signals in Hamp dysregula-
tion. We suggest that similar signals, mediated by allogeneic
T lymphocytes, contribute to the disruption of iron homeo-
stasis and iron accumulation in transplantation recipients.
Such a model does not preclude the involvement of addi-
tional pathways, including, for example, mitochondrial
metabolism [46] or hemoxygenase 1 [47]. Also, at least 1
report [48] suggests that overexpression of FLIPL results in
up-regulation of hypoxia-inducible factor-1a and thereby
affects iron homeostasis [41]. In view of the requirement of
iron for cell survival and the role of FLIPL in the control of cell
death, redundancy of regulatory pathways would not be
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